Abstract：
miRNAs are small endogenous conserved non-coding RNA molecules that regulate post-transcriptional gene expression through mRNA degradation or translational inhibition, modulating nearly 60% of human genes. Cystic diseases are characterized by the presence of abnormal fluid-filled sacs in the body, and though most cysts are benign, they can grow inside tumors and turn malignant. Recent evidence has revealed that the aberrant expression of a number of miRNAs present in extracellular fluids, including plasma or serum, urine, saliva, follicular fluid, and semen, contribute to different cystic pathologies. This review aims to describe the role of different miRNAs in three worldwide relevant cystic diseases: polycystic ovarian syndrome (PCOS), polycystic kidney disease (PKD), and pancreatic cyst tumors (PCTs), as well as their potential use as novel biomarkers.
摘要：
miRNA是内源性保守的非编码小RNA分子，通过mRNA降解或翻译抑制调节转录后基因表达，调节近60%的人类基因。囊性疾病的特征是体内存在异常的充满液体的囊，虽然大多数囊肿是良性的,它们可以在肿瘤内部生长并变成恶性。最近的证据表明，细胞外液中存在的许多miRNA的异常表达，包括血浆或血清，尿液,唾液,卵泡液,还有精液,导致不同的囊性病变。这篇综述旨在描述不同的miRNA在三种全球相关的囊性疾病中的作用：多囊卵巢综合征（PCOS），多囊肾病（PKD），和胰腺囊肿肿瘤（PCT），以及它们作为新型生物标志物的潜在用途。
